Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

SRx Health Solutions (SRXH) EBITDA Margin (2016 - 2025)

SRx Health Solutions' EBITDA Margin history spans 10 years, with the latest figure at 235.21% for Q2 2025.

  • For Q2 2025, EBITDA Margin fell 24877.0% year-over-year to 235.21%; the TTM value through Jun 2025 reached 41.95%, down 2463.0%, while the annual FY2024 figure was 32.73%, 8761.0% up from the prior year.
  • EBITDA Margin reached 235.21% in Q2 2025 per SRXH's latest filing, down from 15.2% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 44.33% in Q4 2024 to a low of 260.71% in Q4 2022.
  • Average EBITDA Margin over 5 years is 58.45%, with a median of 29.57% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: surged 26747bps in 2024, then tumbled -24877bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 45.3% in 2021, then tumbled by -476bps to 260.71% in 2022, then rose by 14bps to 223.13% in 2023, then skyrocketed by 120bps to 44.33% in 2024, then crashed by -631bps to 235.21% in 2025.
  • Per Business Quant, the three most recent readings for SRXH's EBITDA Margin are 235.21% (Q2 2025), 15.2% (Q1 2025), and 44.33% (Q4 2024).